A Phase 2 Clinical Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

Target-HTN was a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter trial designed to evaluate the safety, efficacy and tolerability of orally administered lorundrostat on blood pressure (BP) for the treatment of uncontrolled and resistant hypertension when used as an add-on therapy to stable background treatment of two or more antihypertensive therapies (AHTs).
Full results from Target-HTN were published in the Journal of the American Medical Association (JAMA).